BACKGROUND: New markers to distinguish benign reactive glands from infiltrating ductal adenocarcinoma of the pancreas are needed. DESIGN: The gene expression patterns of 24 surgically resected primary infiltrating ductal adenocarcinomas of the pancreas were compared with 18 non-neoplastic samples using the Affymetrix U133 Plus 2.0 Arrays and the Gene Logic GeneExpress Software System. Gene fragments from 4 genes (annexin A8, claudin 18, CXCL5, and S100 A2) were selected from the fragments found to be highly expressed in infiltrating adenocarcinomas when compared with normal tissues. The protein expression of these genes was examined using immunohistochemical labeling of tissue microarrays. RESULTS: Claudin 18 labeled infiltrating carcinomas in a membranous pattern. When compared with normal and reactive ducts, claudin 18 was overexpressed, at least focally, in 159 of 166 evaluable carcinomas (96%). Strong and diffuse claudin 18 overexpression was most often seen in well-differentiated carcinomas (P=0.02). Claudin 18 was overexpressed in 51 of 52 cases (98%) of pancreatic intraepithelial neoplasia. Annexin A8 was at least focally overexpressed in 149 of 154 evaluable infiltrating carcinomas (97%). S100 A2 was at least focally overexpressed in 118 of 154 evaluable infiltrating carcinomas (77%). Non-neoplastic glands also frequently expressed S100 A2 diminishing its potential diagnostic utility. Immunolabeling with antibodies directed against CXCL5 did not reveal any significant differences in protein expression between infiltrating adenocarcinomas and normal pancreatic ducts. CONCLUSIONS: Claudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas. Furthermore, these may serve as diagnostic markers, as screening tests and as therapeutic targets.
BACKGROUND: New markers to distinguish benign reactive glands from infiltrating ductal adenocarcinoma of the pancreas are needed. DESIGN: The gene expression patterns of 24 surgically resected primary infiltrating ductal adenocarcinomas of the pancreas were compared with 18 non-neoplastic samples using the Affymetrix U133 Plus 2.0 Arrays and the Gene Logic GeneExpress Software System. Gene fragments from 4 genes (annexin A8, claudin 18, CXCL5, and S100 A2) were selected from the fragments found to be highly expressed in infiltrating adenocarcinomas when compared with normal tissues. The protein expression of these genes was examined using immunohistochemical labeling of tissue microarrays. RESULTS:Claudin 18 labeled infiltrating carcinomas in a membranous pattern. When compared with normal and reactive ducts, claudin 18 was overexpressed, at least focally, in 159 of 166 evaluable carcinomas (96%). Strong and diffuse claudin 18 overexpression was most often seen in well-differentiated carcinomas (P=0.02). Claudin 18 was overexpressed in 51 of 52 cases (98%) of pancreatic intraepithelial neoplasia. Annexin A8 was at least focally overexpressed in 149 of 154 evaluable infiltrating carcinomas (97%). S100 A2 was at least focally overexpressed in 118 of 154 evaluable infiltrating carcinomas (77%). Non-neoplastic glands also frequently expressed S100 A2 diminishing its potential diagnostic utility. Immunolabeling with antibodies directed against CXCL5 did not reveal any significant differences in protein expression between infiltrating adenocarcinomas and normal pancreatic ducts. CONCLUSIONS:Claudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas. Furthermore, these may serve as diagnostic markers, as screening tests and as therapeutic targets.
Authors: Noriyoshi Fukushima; Kimberly M Walter; Takashi Uek; Norihiro Sato; Hiroyuki Matsubayashi; John L Cameron; Ralph H Hruban; Marcia Canto; Charles J Yeo; Michael Goggins Journal: Cancer Biol Ther Date: 2003 Jan-Feb Impact factor: 4.742
Authors: Haiyong Han; David J Bearss; L Walden Browne; Robert Calaluce; Raymond B Nagle; Daniel D Von Hoff Journal: Cancer Res Date: 2002-05-15 Impact factor: 12.701
Authors: Patrick Michl; Claudia Barth; Malte Buchholz; Markus M Lerch; Monika Rolke; Karl-Heinz Holzmann; Andre Menke; Heiko Fensterer; Klaudia Giehl; Matthias Löhr; Gerhard Leder; Takeshi Iwamura; Guido Adler; Thomas M Gress Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701
Authors: Denis M McCarthy; Anirban Maitra; Pedram Argani; Anne E Rader; Douglas O Faigel; N Tjarda Van Heek; Ralph H Hruban; Robb E Wilentz Journal: Appl Immunohistochem Mol Morphol Date: 2003-09
Authors: Craig D Logsdon; Diane M Simeone; Charles Binkley; Thiruvengadam Arumugam; Joel K Greenson; Thomas J Giordano; David E Misek; Rork Kuick; Samir Hanash Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Christine A Iacobuzio-Donahue; Anirban Maitra; Mari Olsen; Anson W Lowe; N Tjarda van Heek; Christophe Rosty; Kim Walter; Norihiro Sato; Antony Parker; Raheela Ashfaq; Elizabeth Jaffee; Byungwoo Ryu; Jessa Jones; James R Eshleman; Charles J Yeo; John L Cameron; Scott E Kern; Ralph H Hruban; Patrick O Brown; Michael Goggins Journal: Am J Pathol Date: 2003-04 Impact factor: 4.307
Authors: Dirk Bausch; Stephanie Thomas; Mari Mino-Kenudson; Castillo Carlos Fernández-del; Todd W Bauer; Mark Williams; Andrew L Warshaw; Sarah P Thayer; Kimberly A Kelly Journal: Clin Cancer Res Date: 2010-11-23 Impact factor: 12.531
Authors: Aldona A Karaczyn; Robert Y S Cheng; Gregory S Buzard; James Hartley; Dominic Esposito; Kazimierz S Kasprzak Journal: Ann Clin Lab Sci Date: 2009 Impact factor: 1.256
Authors: H C Harsha; Kumaran Kandasamy; Prathibha Ranganathan; Sandhya Rani; Subhashri Ramabadran; Sashikanth Gollapudi; Lavanya Balakrishnan; Sutopa B Dwivedi; Deepthi Telikicherla; Lakshmi Dhevi N Selvan; Renu Goel; Suresh Mathivanan; Arivusudar Marimuthu; Manoj Kashyap; Robert F Vizza; Robert J Mayer; James A Decaprio; Sudhir Srivastava; Samir M Hanash; Ralph H Hruban; Akhilesh Pandey Journal: PLoS Med Date: 2009-04-07 Impact factor: 11.069